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Abstract
Purpose Few studies have correlated computed tomog-
raphy enterography (CTE) findings with Crohn’s disease
(CD) clinical and biochemical activity. The aim of this
study was to evaluate correlations between CTE findings
with CD activity.
Materials and methods The CTE datasets from 62
patients were retrospectively reviewed for different
parameters: bowel wall thickening and hyperenhancement,
mesenteric alterations, abdominal free fluid and compli-
cations related to the disease (fistulas, strictures, absces-
ses). Activity was assessed using the Crohn’s Disease
Activity Index (CDAI) and some biochemical markers (C-
reactive protein, erythrocyte sedimentation rate, alpha
2-globulins, fibrinogen, platelets, haemoglobin). Correla-
tions between CTE parameters, clinical activity score and
laboratory parameters were assessed by logistic regression.
Results CDAI was significantly correlated with increased
fat density (p = 0.03) and intestinal strictures (p = 0.04).
Platelet counts were elevated in patients with enlarged
mesenteric lymph nodes (p = 0.009) and the comb sign
(p = 0.05). Serum alpha 2-globulins were higher in the
presence of the comb sign (p = 0.03).
Conclusion The CTE finding of perienteric inflammation
(increased fat density) and vascular engorgement of the
vasa recta in CD patients suggest that the disease is clini-
cally active and that these patients may require more
aggressive treatment than patients without these findings.
Keywords Crohn disease  Radiography  Small
intestine  Radiography  Computed tomography
Introduction
Assessment of inflammatory activity in Crohn’s disease
(CD) has become crucial to drive therapeutic choices and
monitor their effect [1]. In the past, this evaluation was
based on clinical indexes, mainly the Crohn’s Disease
Activity Index (CDAI), integrated by laboratory parame-
ters including C-reactive protein (CRP), erythrocyte sedi-
mentation rate (ESR), and orosomucoids, and endoscopic
findings [2, 3]. Indeed, endoscopy can assess only mucosal
inflammation, which, in a transmural disease like CD,
might not be enough [4].
Recently, a few papers have suggested the role of
radiological techniques such as computed tomography
enteroclysis or enterography (CTE) and magnetic reso-
nance enteroclysis or enterography (MRE) not only in
detecting extramural complications but also in the evalu-
ation of disease activity [5–9].
The CTE finding of either enteric signs such as mural
stratification and hyperenhancement or perienteric signs
like mesenteric hypertrophy or engorged vasa recta, the so-
called ‘‘comb sign’’, has been found to correlate either with
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endoscopic or histological inflammation or with acute-
phase proteins, with sometimes discrepant results [6, 7, 10–
12]. The importance of recognising the different patterns of
disease, especially early in the disease course, may help in
tailoring specific therapies, predicting future complica-
tions, and possibly offering better timing of surgical
interventions [13]. A good classification of the patient is of
primary importance, and sometimes a clinical suspicion is
not confirmed on more invasive investigation [14].
In this context, CTE today appears as a valid technique
for the detection of disease complications, and thus a valid
alternative for disease staging. It seems to be a very
powerful technique which can be performed quickly in
most radiological departments, even though some concerns
have been raised regarding radiation exposure [15, 16]. In
this respect, correlating CD clinical activity with the CTE
findings could help to select patients to be referred for
CTE, reducing unnecessary radiation exposure [9].
However, the relationships between the CTE findings of
bowel inflammatory activity, and clinical and serum bio-
chemical markers of inflammation have not yet been
thoroughly investigated. The aim of this study was to
correlate the CTE findings with CD clinical activity,
assessed by CDAI, and biochemical activity, assessed by a
comprehensive panel of markers including ESR, CRP,
alpha 2-globulins, fibrinogen, platelets and haemoglobin.
Materials and methods
Patients
We retrospectively reviewed all the clinical records of CD
patients followed up in our inflammatory bowel disease
clinic (a tertiary referral centre for gastroenterological
disease), between September 2008 and September 2011.
Patients were included if they had a definite diagnosis of
small bowel CD based on clinical, endoscopic and histo-
logical findings [17] and had been subjected to CTE,
ordered as part of routine clinical workup by experienced
gastroenterologists for suspicion of strictures or abscesses.
Exclusion criteria, routinely applied at our department for
this type of studies, were age younger than 18 years, renal
insufficiency (serum creatinine [2 mg/dL), pregnancy,
intestinal obstruction and documented allergic reaction to
iodinated contrast material. The study population consisted
of 62 patients (33 male; median age 40 years; range
20–66 years; median duration of disease 52 months; range
1–468 months) with CD. At the time of CTE examination,
61.3 % of patients were treated with steroids and mesal-
azine, 12.9 % were on conventional immunomodulators
(azathioprine or methotrexate), 14.5 % were receiving anti-
TNF agents (infliximab or adalimumab) and 12.9 % were
on aminosalicylates alone. The demographic and clinical
characteristics of patients enrolled in the study are reported
in Table 1. Clinical activity was assessed using the CDAI.
Biochemical activity was evaluated with clinical data and
biochemical data, obtained within 2 weeks before CTE
(ESR, CRP, complete blood count, serum alpha 2-globulins
and fibrinogen). In 40 patients CDAI was higher than 150,
while in the remaining 22 CDAI was \150, so the disease
was considered in remission. All patients enrolled were
Table 1 Demographic, clinical and laboratory features of 62 con-
secutive Crohn’s disease patients
Gender
Male 33 (53.2)
Female 29 (46.8)
Age (years) 42 (15)
Duration of disease (months) 75 (94)
Age at diagnosis
\40 41 (66.1)
[40 21 (33.9)
Location
L1 (terminal ileum) 20 (32.3)
L2 (colon) 4 (6.5)
L3 (ileocolon) 36 (58.0)
L4 (upper gastrointestinal) 2 (3.2)
Behaviour
B1 (nonstricturing nonpenetrating) 13 (21.0)
B2 (stricturing) 24 (38.7)
B3 (penetrating) 9 (14.5)
Stricturing and penetrating 16 (25.8)
Perianal involvement 10 (16.1)
Medical treatmenta
Only aminosalicylatesb 8 (12.9)
Any corticosteroidsc 38 (61.3)
Any immunosuppressive agentsd 8 (12.9)
TNF-antagoniste 9 (14.5)
Current smoker 22 (35.5)
ESR (mm/h) 24 (2–136)
CRP (mg/dL) 0.76 (0.02–25.8)
Platelet count (9103/mm3) 286 (110–567)
Fibrinogen (mg/dL) 379 (234–588)
Alpha 2-globulins (g/dL) 0.88 (0.48–1.5)
Haemoglobin (g/dL) 12.2 (6.5–15.6)
Data are given as median (range) or as number of cases (%)
CDAI Crohn’s Disease Activity Index, ESR erythrocyte sedimentation
rate, CRP C-reactive protein
a Some patients with more than one treatment
b Mesalazine, sulfasalazine
c Budesonide, prednisone, methylprednisolone
d Azathioprine, 6-mercaptopurine, methotrexate
e Infliximab, adalimumab
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asked to sign an informed consent form for the processing
of their personal data in accordance with the law, and each
patient had also read an informative report about the
tutelage of the personal data, in accordance with the same
law. Statistical analyses were done after removing personal
data.
CTE technique
Prior to the examination, all patients underwent an intes-
tinal preparation according to the following plan: a diet
free of fruit and vegetables for at least 3 days before the
examination; a semiliquid diet and 2 L of water and
macrogol 4,000 solution (Selg-Esse 1000, PROMEFARM,
Milan, Italy) the day before the examination. This was
necessary to eliminate residual faeces, avoid reflux into the
small bowel and ensure a faster transit of the negative
intraluminal contrast agent. The patients obtained adequate
small bowel distension with oral administration of 2 L of
iso-osmotic polyethylene glycol (PEG) solution within
60 min prior to scanning. PEG was chosen for its no
osmotic effects and for its pleasant, sweet taste, which
makes it more acceptable to patients. To minimise potential
artefacts due to peristaltic bowel movement, to obtain
homogeneous small bowel distension and to reduce
abdominal discomfort, all patients underwent intravenous
(IV) administration of an anticholinergic compound, 20 mg
of N-butyl-joscine bromide (Buscopan, Boehringer Ingel-
heim, Reggello, Florence, Italy) 10 min before the CT scan
[18]. All patients were studied with a 64-slice MDCT
scanner (Brilliance 64, Philips Medical System, Cleveland,
Ohio, USA) using the following scan parameters: colli-
mation, 64 9 0.625 mm; gantry rotation time, 420 ms;
slice thickness, 1.5 mm; slice increment, 0.7 mm, 140 kV,
250 mAs. We used the CT scanner’s automatic dose
reduction method for all the examinations. The dose
reduction software allowed modulation of the mAs
parameter during the scan using a maximum of 250 mAs
with a dose–length product mean of 730 mGy*cm with a
range of 678–923 mGy*cm [19–21]. The examinations
were performed 50 s after the IV administration of 1.5 mL/
kg of iodinated nonionic contrast medium (iodixanol,
Visipaque 320, GE Healthcare S.r.l. Milan, Italy) at a mean
flow rate of 3 mL/s [18]. The CTE scan was performed
with the patient in the supine position, and the scanning
volume was acquired from the diaphragm to the perineum
during a single breath-hold.
Visual image evaluation
Acquired data were analysed on an advanced computer
workstation where, besides the axial images, multiplanar,
maximum intensity projection and volume rendering
reconstructions were visualised. CT images were analysed
in random order and were reviewed by two experienced
gastrointestinal radiologists, blinded to all endoscopic and
clinical data to ensure objective interpretation of image
findings. To evaluate intraobserver variability, images were
blindly re-analysed by the same observer after 2 weeks. To
evaluate interobserver variability, all the images were
presented in random order to both observers, who were
unaware of each other’s results. In each patient we assessed
site and number of abnormal bowel segments, bowel wall
thickening (BWT), mural hyperenhancement, mural strat-
ification and mesenteric alterations (Table 2). BWT was
defined as pathological if C3 mm on an adequately dis-
tended loop [22]. Mural hyperenhancement was defined as
segmental enhancement in all or part (in the case of mural
stratification) of the small bowel wall, greater than in the
adjacent small bowel loops. Each of these bowel wall
characteristics was rated as present or absent. Mesenteric
alterations included fibro-fatty proliferation (known as
‘‘creeping fat’’ of the mesentery), increased fat density,
hypervascularity (consisting of the presence of the ‘‘comb
sign’’) and lymph nodes. Fibro-fatty proliferation refers to
Table 2 Computed tomography enterography features of 62 con-
secutive Crohn’s disease patients
CTE findings CD (n = 62)
Bowel wall thickening 49 (79.0)
Mural hyperenhancement 51 (82.2)
Fibro-fatty proliferation
0 9 (14.5)
1 33 (53.2)
2 20 (32.3)
Increased fat density
0 7 (11.3)
1 31 (50.0)
2 24 (38.7)
Comb sign
0 4 (6.5)
1 30 (48.4)
2 28 (45.1)
Adenopathies
\1.5 cm 41 (66.1)
1.5–3 cm 13 (21.0)
[3 cm 8 (12.9)
Peritoneal effusion 31 (50.0)
Strictures 20 (32.2)
Fistulas 22 (35.5)
Abscesses 12 (19.3)
Data are given as number of cases (%)
CTE computed tomography enterography, CD Crohn’s disease, 0
absent, 1 mild-moderate, 2 severe
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fatty deposition along the mesenteric border of bowel
segments affected by CD; it was defined as a focally
increased and inhomogeneous fluid attenuation in the
mesenteric fat [?20/?60 Hounsfield units (HU)], com-
pared with the appearance of subcutaneous fat or perien-
teric fat adjacent to noninflamed bowel loops [23].
Increased fat density refers to fluid density in the fat sur-
rounding thickened or abnormally enhancing bowel,
resulting from inflammatory infiltration of the perienteric
adipose tissue. The comb sign refers to hypervascularity of
the involved mesentery because of the presence of dilated
and tortuous vasa recta that penetrate the bowel wall per-
pendicular to the bowel lumen, mimicking the appearance
of a comb [24]. Mesenteric lymph nodes located near the
affected intestinal segments were considered pathological
if their transverse diameter was [15 mm [25]. Each of
these mesenteric effects were graded along a three-point
scale as not present (0), definitely present to a mild-mod-
erate (1) or a severe (2) degree.
Finally, the presence of abdominal free fluid and other
complications related to the disease (fistulas, strictures,
abscesses) were assessed. All the CTE features are sum-
marised on Table 2.
Statistical analysis
All continuous variables were described as median and
range, while categorical variables were expressed as fre-
quency and percentage. The patients were grouped
according to the clinical activity of disease: inactive (CDAI
\150); mild activity (CDAI 150–220); moderate activity
(CDAI 220–450). To explore univariate associations in the
distribution of categorical data, the Chi-squared test or
Fisher’s exact test was used, as appropriate. Differences in
mean continuous variables between groups of patients were
analysed by the t test. A p value \0.05 was considered
statistically significant. Multiple linear regression analysis
was performed to identify independent predictors of CTE
findings as continuous dependent variables in all groups of
patients. Variables found to be associated with the depen-
dent variable at univariate analyses were included in
multivariate regression models. Multiple logistic regression
models were used to assess the relationship of CTE find-
ings to demographic, clinical and laboratory characteristics
of CD patients. Regression analyses were performed using
PROC LOGISTIC, PROC REG, and subroutines in Sta-
tistical Analysis Software (SAS Institute, Inc., Cary, NC).
Results
According to the Montreal classification [26], CD patients
presented the following disease location: L1, 32.3 %; L2,
6.5 %; L3, 58.0 % and L4, 3.2 %. 21 % had nonstricturing
nonpenetrating disease, 38 % stricturing, 9 % penetrating,
16 % both stricturing and penetrating disease and ten
patients (16 %) had perianal involvement. In 40 patients,
CDAI was higher than 150, while in the remaining 22
CDAI was \150, so the disease was considered in
remission.
Twenty patients (32.2 %) showed intestinal strictures
(Fig. 1); 19 of them also showed bowel wall hyperen-
hancement and comb sign, and were therefore classified as
inflammatory stenosis (Figs. 2, 3). Other signs were fistulas
in 22 (35.5 %, Fig. 4) and abscesses in 12 (19.3 %, Fig. 5).
All the CTE findings are summarised in Table 2, while the
association between CTE findings according to CD clinical
activity is summarised in Table 3. Univariate analysis
showed that the presence of increased fat density
(p = 0.008) and intestinal strictures (p = 0.03) were sig-
nificantly associated with CDAI score above 150 (Table 3).
Furthermore, the presence of abdominal free fluids was
marginally related to clinical disease activity (p = 0.054).
Based on the multivariate linear logistic regression model,
the increased fat density [p = 0.03, odds ratio (OR) 2.5,
95 % confidence interval (CI) 1.057–5.923] and intestinal
Fig. 1 Male patient with mild
Crohn’s disease activity (CDAI
383). Axial and coronal
contrast-enhanced images of
computed tomography
enterography show an ileal
stricture (arrowhead)
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strictures (p = 0.04, OR 3.0, 95 % CI 1.042–8.613) were
significantly and independently associated with an elevated
CDAI score (Figs. 2, 6). Univariate analysis showed that
the presence of enlarged mesenteric lymph nodes
(p = 0.009) and comb sign (p = 0.05) were significantly
associated with a high platelet count (Table 4). Further-
more, the serum alpha 2-globulins were the only serum
biomarker significantly and independently associated with
the presence of the comb sign (p = 0.03, OR 13.9, 95 % CI
1.158–168.491).
The correlation between the two observers in the visu-
alisation of Crohn’s disease bowel manifestations was
found to be 98.4 %, with only one case of disagreement.
Intraobserver variability did not show a significant
difference.
Discussion
In referral centres, CTE has outnumbered barium exam-
inations to assist in Crohn’s disease diagnosis [23, 27].
CTE has been reported to influence disease management in
28 % of cases, mainly due to detection of complications
and assessment of disease activity [27]. Moreover, radio-
logical findings are mostly relevant for assessing the
‘‘damage score’’ as well as mucosal and histological
healing [28]. CTE provides both anatomical and practical
advantages: depiction of the entire bowel wall, multiplanar
imaging and no obscuration of small bowel loops due to
superimposition, and better evaluation of both luminal and
extramural manifestations [29]; in addition, it is not an
operator-dependent technique [30]. From the patient’s
Fig. 2 Patient with mild
Crohn’s disease activity (CDAI
162). Computed tomography
enterography shows increased
fat density with the comb sign
(arrowhead) and a bowel
stricture (arrow) in the axial
contrast-enhanced images and
in an oblique coronal contrast-
enhanced reconstruction image
Fig. 3 Female patient with
mild Crohn’s disease activity
(CDAI 320). Axial and coronal
contrast-enhanced images of
computed tomography
enterography show increased fat
density and the comb sign with
nodal involvement (arrow), and
mural hyperenhancement of the
small bowel wall with an
inflammatory pseudopolyp
(arrowhead)
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perspective, CTE has the advantage of being less invasive
because it does not require intubation or uncomfortable
palpation, it only requires getting on and off the table once,
and it is generally faster. CTE adds useful information to
the clinical assessment providing definition of extraluminal
involvement and ensuring stricture detection and
characterisation.
Our study shows that a CTE finding of increased fat
density has a good correlation with the CDAI score.
Although the CDAI has been criticised because of its
subjectivity and interobserver variability, it remains the
most widely used index for evaluating outcome in clinical
trials on Crohn’s disease [31]. Increase in fat density is a
highly specific marker of active CD, reflecting the presence
of inflammatory infiltrate within the perienteric fat due to
mesenteric adipocytes which are supposed to play a major
role in the CD inflammatory cascade [32]. Compared to
fibro-fatty proliferation, the increased fat density is an
earlier change and is also more specific than bowel wall
thickening, which could give false-positive findings in the
presence of underdistended bowel loops.
Conflicting data have appeared in the medical literature
concerning the relationship between radiological signs of
inflammation (approached by either CTE or MRE) and
disease activity in CD. Maccioni et al. [33] reported a
significant correlation between MR signs of intestinal
inflammation (oedema in the perienteric fat, wall thicken-
ing, contrast enhancement) with a biological activity score
which included white blood cells, orosomucoid levels and
CRP in 20 CD patients. These results were not confirmed
by other authors [34–36]. Few data exist about the rela-
tionship between signs of perienteric inflammation, such as
those explored in our study, with clinical or biochemical
indices of activity. Lee et al. [37] first described the asso-
ciation of prominent perienteric or pericolic vasculature
and active CD. Colombel et al. [4] found a significant
relationship between radiological findings of perienteric
inflammation expressed by increased fat density and CRP.
Minordi et al. [8] evaluated both mural signs (parietal
thickness, target sign or alternating rings of low and high
density in the bowel wall) and extraenteric inflammation.
There was a positive correlation between the target sign
and fibro-fatty proliferation with the CDAI and among wall
thickness, the comb sign and perienteric stranding with
CRP. When we explored the relationship between the
biomarkers and the CTE findings, we found a correlation of
alpha 2-globulins and platelet count with vascular extra-
luminal findings (comb sign). Alpha 2-globulins are a
fraction of serum proteins containing orosomucoids, in
particular alpha 1-acid glycoprotein, which, though less
commonly used in clinical practice, had been shown to
have a better correlation with CDAI than CRP [38]. The
relationship with the comb sign, which is an expression of
Fig. 4 Male patient, 52-year
old, with moderate Crohn’s
disease activity (CDAI 195).
Axial and coronal contrast-
enhanced images of computed
tomography enterography show
an ileocolic fistula (arrow) and
mural hyperenhancement of the
small bowel wall (arrowhead)
Fig. 5 Female patient, 60-year old, with moderate Crohn’s disease
activity (CDAI 207). Axial images of computed tomography enter-
ography show an ileocolic fistula (arrow) and an abscess (arrowhead)
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more advanced and extensive CD, could suggest the pre-
sence of prolonged active disease. These results may pro-
vide new insight into the meaning and clinical implications
of elevated expression of these markers in Crohn’s patients.
Many studies have connected vascular inflammation to the
pathogenesis of inflammatory bowel disease [39, 40]. CTE
may offer a noninvasive way to detect vascular abnor-
malities in Crohn’s disease that was not previously avail-
able. There are some discrepancies between our results and
those of previous studies, which could be explained by
differences in sample size, patient recruitment and referral
and heterogeneity of technical approach. Minordi et al. [8]
used both enterography and enteroclysis in their study,
whereas Colombel et al. [4] enrolled patients undergoing
colonoscopy and the primary endpoint of the study was to
correlate CTE with endoscopy and serum biomarkers and
not with clinical activity. Our case series has the advantage
of being totally homogenous since all patients are referred
to the radiology department by a single gastroenterology
team dedicated to the care of IBD patients and the technical
approach was uniform. Our study confirms the role of CTE
as a useful tool not only in the diagnostic workup of sus-
pected CD but also in the evaluation of disease activity,
which we believe is an integrated process which involves
clinical symptoms and signs, serum acute-phase reactants
and endoscopic findings.
To our knowledge, few studies in the literature have
correlated CDAI, biochemical activity and CTE signs with
attention focused also on nodal involvement and abdominal
free fluid. The major limitation of the study pertains to the
CT technique and is the use of ionising radiation that we
tried to limit by using dose reduction software. In con-
clusion, CTE might help to better address and monitor
response to therapy, for example, to define the so-called
‘‘window of opportunity’’ for biologics, and this aspect
deserves further studies since it has not been evaluated in
the present study or in the literature. However, to prove the
value of CTE in the clinical assessment of Crohn’s disease,
we need prospective studies that can determine whether the
Table 3 Univariate and multivariate analyses of computed tomography enterography findings associated with the Crohn’s disease activity index
Variable CDAI Univariate analysis Multivariate analysis
\150 (n = 22) 150–220 (n = 17) 220–450 (n = 23) p value OR (95 % CI) p value
BWT 17 (77.3) 15 (88.2) 17 (73.9) 0.529 – –
MH 18 (81.8) 15 (88.2) 18 (78.2) 0.715 – –
FP 15 (68.2) 16 (94.1) 22 (95.6) 0.371 – –
IFD 17 (77.3) 16 (94.1) 22 (95.6) 0.008 2.501 (1.057–5.923) 0.03
Comb sign 19 (86.4) 17 (100) 22 (95.6) 0.683 – –
Nodes 6 (27.3) 8 (47.0) 7 (30.4) 0.297 – –
FF 7 (31.8) 10 (58.8) 14 (60.8) 0.054 1.365 (0.470–3.969) 0.56
Strictures 4 (18.2) 5 (71.4) 11 (47.8) 0.034 2.995 (1.042–8.613) 0.04
Fistulas 4 (18.2) 9 (52.9) 9 (39.1) 0.175 – –
Abscesses 3 (13.6) 5 (71.4) 4 (17.4) 0.784 – –
Data are given as number of cases (%)
CDAI Crohn’s Disease Activity Index, OR odds ratio, CI confidence interval, BWT bowel wall thickening, MH mural hyperenhancement, FP
fibro-fatty proliferation, IFD increased fat density, FF abdominal free fluid
Fig. 6 Computed tomography enterography: axial contrast-enhanced
images in a 39-year-old male with active Crohn’s disease (CDAI 256)
demonstrating increased fat density and comb sign (arrowhead)
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informations gained from CTE actually change clinical
decision-making and clinical outcomes.
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